

PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY AGREEMENT
CONVEYING PARTY DATA	
Name	Execution Date
BBM Holdings, Inc.	03/18/2009
RECEIVING PARTY DATA	
Name:	YA Global Investments, L.P.
Street Address:	101 Hudson Street, Suite 3700
City:	Jersey City
State/Country:	NEW JERSEY
Postal Code:	07302
PROPERTY NUMBERS Total: 23	
Property Type	Number
Patent Number:	6696422
Patent Number:	6355226
Patent Number:	5807839
Patent Number:	5807840
Patent Number:	5849196
Patent Number:	6312602
Patent Number:	6303153
Patent Number:	6528098
Patent Number:	7439234
Patent Number:	7067139
Patent Number:	7179592
Patent Number:	6670118
Patent Number:	6921542
Patent Number:	7074767
Patent Number:	6440658

OP \$920.00 6696422

500865029

PATENT
REEL: 022708 FRAME: 0679

Patent Number:	6268349
Patent Number:	7465711
Application Number:	60544610
Application Number:	60584851
Application Number:	60605320
Application Number:	60687545
Application Number:	11991217
Application Number:	11921484

CORRESPONDENCE DATA

Fax Number: (802)862-7512

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 802-863-2375

Email: patip@drm.com

Correspondent Name: Jamie T. Gallagher, Esq.

Address Line 1: 199 Main Street

Address Line 4: Burlington, VERMONT 05401

ATTORNEY DOCKET NUMBER:	13083-00002
-------------------------	-------------

NAME OF SUBMITTER:	Jamie T. Gallagher
--------------------	--------------------

Total Attachments: 7

source=BBM02_SecurityAgmt_BBMtoYAGlobal#page1.tif

source=BBM02_SecurityAgmt_BBMtoYAGlobal#page2.tif

source=BBM02_SecurityAgmt_BBMtoYAGlobal#page3.tif

source=BBM02_SecurityAgmt_BBMtoYAGlobal#page4.tif

source=BBM02_SecurityAgmt_BBMtoYAGlobal#page5.tif

source=BBM02_SecurityAgmt_BBMtoYAGlobal#page6.tif

source=BBM02_SecurityAgmt_BBMtoYAGlobal#page7.tif

SECURITY AGREEMENT

(Patent)

THIS SECURITY AGREEMENT (PATENT) ("Agreement"), is entered into and made effective as of March 18, 2009, by and between **BBM HOLDINGS, INC.**, a Utah corporation with its principal place of business located at 1245 Brickyard Road, Suite 590, Salt Lake City, Utah 84106 (the "Company"), in favor of **YA GLOBAL INVESTMENTS, L.P.** (the "Secured Party").

WITNESETH:

WHEREAS, pursuant to that certain Secured Party's Bill of Sale of even date herewith between the Parent and the Secured Party (the "Bill of Sale") the Secured Party shall sell to the Company all of Advanced Viral Research Corp.'s and Triad Biotherapeutics, Inc.'s right, title, and interest in and to the certain personal property;

WHEREAS, pursuant to the Securities Purchase Agreement of even date herewith between the Parent and the Secured Party (the "Securities Purchase Agreement"), the Parent has issued to the Secured Party a secured convertible debenture (including any debentures issued in exchange, transfer or replacement thereof) (the "Convertible Debenture");

WHEREAS, to induce the Secured Party to accept the Convertible Debenture and enter into the Securities Purchase Agreement, the Bill of Sale, and the documents entered into in connection therewith, (collectively referred to as the "Transaction Documents"), the Company hereby grants to the Secured Party a security interest, in and to the Patent Collateral (as defined below) to secure all of the Obligations (as defined below).

WHEREAS, in connection with the Securities Purchase Agreement, the Company has agreed to provide the Secured Party a general security interest in Pledged Property (as this term is defined in the Security Agreement by and between the Company and the Secured Party, of even date herewith (together with all amendments, supplements, restatements and other modifications, if any, from time to time made thereto, the "Security Agreement");

WHEREAS, the Company has duly authorized the execution, delivery and performance of this Agreement;

NOW THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, the Company agrees as follows:

SECTION 1. Definitions. Unless otherwise defined herein otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided in the Securities Purchase Agreement.

(a) "**Obligations**" shall have the meaning assigned to it in the Security Agreement.

SECTION 2. Grant of Security Interest. For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, to secure the payment and performance of all of the Obligations of the Company, the Company does hereby mortgage, pledge and hypothecate to the Secured Party and grant to the Secured Party a security interest in all of the following property (the "**Patent Collateral**"), now owned and existing:

(a) all letters patent and applications for letters patent throughout the world, including all patent applications in preparation for filing anywhere in the world and including each patent and patent application referred to in Schedule A hereto;

(b) all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the items described in clause (a);

(c) all patent licenses and other agreements providing the Company with the right to use any of the items of the type referred to in clauses (a) and (b), including each patent license referred to in Schedule A hereto;

(d) the right to sue third parties for past, present or future infringements of any Patent Collateral described in clauses (a) and (b) and, to the extent applicable, clause (c); and

(e) all proceeds of, and rights associated with, the foregoing, (including license royalties and proceeds of infringement suits), and all rights corresponding thereto throughout the world.

SECTION 3. Security Agreement. This Agreement has been executed and delivered by the Company for the purpose of recording the security interest of the Secured Party in the Patent Collateral relating to patents referred to in Schedule A with the United States Patent and Trade Marks Office, to the extent it may be so registered therein. The security interest granted hereby has been granted as a supplement to, and not in limitation of, the security interest granted to the Secured Party under the Security Agreement. The Security Agreement (and all rights and remedies of the Secured Party thereunder) shall remain in full force and effect in accordance with its terms.

SECTION 4. Release of Security Interest. Upon payment in full of all Obligations the Secured Party shall, at the Company's expense, execute and deliver to the Company all instruments and other documents as may be necessary or proper to release the lien on any security interest in the Patent Collateral which has been granted hereunder.

SECTION 5. Acknowledgement. The Company does hereby further acknowledge and affirm that the rights and remedies of the Secured Party with respect to the security interest in the Patent Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by references herein as if fully set forth herein.

SECTION 6. Securities Purchase Agreement. Notwithstanding any other term or provision hereof, in the event that any provisions hereof contradict and are incapable of being construed in conjunction with the provisions of the Security Agreement, the provisions of the Security Agreement shall take precedence over those contained herein and any encumbrance

expressly permitted under the Security Agreement to exist or to remain outstanding shall be permitted hereunder and thereunder. This instrument, document or agreement may be sold, assigned or transferred by the Agent in accordance with the terms of the Securities Purchase Agreement.

SECTION 7. Counterparts. This Agreement may be executed by the parties hereto in several counterparts, each of which shall be deemed to be an original and all of which shall constitute together but one and the same agreement.

IN WITNESS WHEREOF, the parties hereto have executed this Security Agreement as of the date first above written

BBM HOLDINGS, INC.

By: 

Name: Arshen Ziper

Title: 

STATE OF _____)
COUNTY OF _____) SS:

BEFORE ME, a Notary Public in and for said County and State, personally appeared the above-named _____ who acknowledged that he/she did sign the foregoing agreement and that the same is his/her free act and deed.

IN TESTIMONY WHEREOF, I have hereunto set my hand and official seal at _____, _____, this ____ day of _____, 2009.

Notary Public

IN WITNESS WHEREOF, the parties hereto have executed this Security Agreement
as of the date first above written.

SECURED PARTY:
YA GLOBAL INVESTMENTS, L.P.

By: Yorkville Advisors, LLC
Its: Investment Manager

By: 
Name:
Title:

Schedule A

Security Agreement (Patent)

US PATENTS

<u>APPLICATION OR PATENT NO.</u>	<u>ISSUE OR FILING DATE</u>	<u>TITLE</u>
6,696,422	05/21/99	Combination Therapy for HIV Infections
6,355,226	08/30/00	Topical Treatment of Eye Disease and Eye Afflictions
5,807,839	04/15/97	Method for Stimulating Red Blood Cell Production
5,807,840	11/04/97	Method for Treating Canine Distemper
5,849,196	10/07/96	Composition Containing Peptides and Nucleic Acids and Methods of Making Same
6,312,602	12/15/98	Peptide-Containing Compositions, and Methods of Making and using same
6,303,153	06/25/99	Preparation of a Therapeutic Composition
6,528,098	01/17/01	Preparation of a Therapeutic Composition
7,439,234	06/05/03	Method for Treating Cancer Patients undergoing Chemotherapy
7,067,139	05/21/99	Method for Training Autoimmune Diseases
7,179,592	08/01/01	Size-Exclusion-Based Extraction of Affinity Ligands and Active Compounds from Natural Samples
6,670,118	11/10/98	Method for Treating Papillomavirus Infections
6,921,542	07/22/02	Preparation of a Therapeutic Composition
7,074,767	07/22/02	Preparation of a Therapeutic Composition
6,440,658	11/03/00	Assay Method for Determining Product R's Effect on Adenovirus Infection of Hela Cells
6,268,349	04/15/97	Method for Treating B19 Parvovirus Infections

11/346,146	02/01/06	Preparation of a Therapeutic Composition
7,465,711	08/06/07	Treatment of Cancers of Lymphocytic Cells with Product R
60/544,610	02/13/04	Method of Treating Carcinomas
60/584,851	07/01/04	Protocol for the Clinical Testing of Product R For Effectiveness in the Treatment of Severe Acute Respiratory Syndrome (SARS)
60/605,320	08/27/04	Methods of Promoting Wound Healing
60/687,545	06/02/05	Methods of Promoting Wound Healing
11/991,217	02/27/08	Methods of Promoting Wound Healing
11,921,484	12/03/07	Methods for Providing Palliative Care with AVR118